近日,由阿斯利康与第一三共共同开发与商业化的德曲妥珠单抗在中国取得新突破:其序贯THP疗法用于HER2阳性早期乳腺癌新辅助治疗的适应症实现“全球首批”,中国患者成为全球最早受益于这一创新疗法的群体。 这并非德曲妥珠单抗在中国的首次亮相。自2023年首次获批以来,这款被称为“大魔王”的抗体偶联药物(ADC)在中国接连拿下七项适应症,覆盖乳腺癌、肺癌、胃癌等多个领域。 获批节奏之密集,归于科学突破...
Source Link近日,由阿斯利康与第一三共共同开发与商业化的德曲妥珠单抗在中国取得新突破:其序贯THP疗法用于HER2阳性早期乳腺癌新辅助治疗的适应症实现“全球首批”,中国患者成为全球最早受益于这一创新疗法的群体。 这并非德曲妥珠单抗在中国的首次亮相。自2023年首次获批以来,这款被称为“大魔王”的抗体偶联药物(ADC)在中国接连拿下七项适应症,覆盖乳腺癌、肺癌、胃癌等多个领域。 获批节奏之密集,归于科学突破...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.